Myriad Genetics (MYGN) Misses Q4 EPS by 6c; Issues Weak Q1, FY17 Outlook
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Myriad Genetics (NASDAQ: MYGN) reported Q4 EPS of $0.32, $0.06 worse than the analyst estimate of $0.38. Revenue for the quarter came in at $186.5 million versus the consensus estimate of $187.92 million.
Myriad Genetics sees Q1 2017 EPS of $0.25-$0.27, versus the consensus of $0.43. Myriad Genetics sees Q1 2017 revenue of $167-170 million, versus the consensus of $192.0 million.
Myriad Genetics sees FY2017 EPS of $1.00-$1.10, versus the consensus of $1.65. Myriad Genetics sees FY2017 revenue of $740-760 million, versus the consensus of $755.5 million.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Corelogic (CLGX) Tops Q3 EPS by 7c, Expects to Achieve Upper Ends of FY16 Guidance
- American Campus Communities (ACC) Tops Q3 FFO by 2c
- Berkshire Hills Bancorp (BHLB) Misses Q3 EPS by 1c
Create E-mail Alert Related CategoriesEarnings, Guidance, Hot Guidance, Trading Halts
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!